The Leukemia & Lymphoma Society of Canada (LLSC) is Canada's largest voluntary health organization dedicated to funding blood cancer research, education and patient services. The mission of LLSC is to cure all forms of blood cancer and improve the quality of life of patients and their families. Since its founding in 1955, LLSC has invested millions of dollars for research specifically targeting blood cancers and continues to fund innovative research to advance more breakthrough therapies.
To this end, LLSC also supports community service programs, advocacy, and public and professional education. LLSC supports research through the Operating Grant (OG) research grant program.
The Operating Grant is a two-year grant designed to provide funding to research that may ultimately lead to a significant change in the understanding, diagnosis, or treatment of leukemia, lymphoma, myeloma, myelodysplastic syndromes, and myeloproliferative neoplasms.
LLSC will provide funding up to a maximum of $100,000 per year for two years (up to a maximum total of $200,000 for the two years). Grant funding will be made in two annual payments.
Partnership Funding Opportunities for 2024
The LLSC is pleased to announce a new research funding partnership with AstraZeneca Canada to co-fund two (2) grants in this competition. AstraZeneca is a global, innovation-driven biopharmaceutical business with a focus on the discovery, development, and commercialization of medicines that transform lives. In addition to bringing life-changing medicines to patients, AstraZeneca Canada is committed to supporting research that helps to better understand the complexities of cancers. As such, AstraZeneca Canada is partnering with the LLSC to drive Canadian research that aims to strengthen the understanding, diagnosis and treatment of blood cancers to help improve patient outcomes.
The LLSC is also partnered with Myeloma Canada to fund one (1) grant in this competition. Myeloma Canada is the only national charitable organization created by, and for, Canadians impacted by multiple myeloma. The organization is driven to improve the lives of those affected by myeloma by empowering the community through awareness, education and advocacy programs, and supporting clinical research to find a cure. Since it was founded in 2005, Myeloma Canada has been making myeloma matter. Applications relating to the treatment of multiple myeloma should aim to accelerate the development of Canadian academic cellular therapies.
The LLSC is pleased to continue our partnership with the Cancer Research Society (CRS) to cofund five (5) Operating Grants in this funding cycle. The CRS is a national not-for-profit organization whose sole mission is to fund research on all types of cancer, thereby contributing to the advancement of science aimed at preventing, detecting, and treating the disease. Funds for competitive applications will be awarded on the basis of scientific merit, using a priority rating, and will include evaluation of ethical research.
The Scientific Review Panel (SRP) will review all applications. New investigators as well as established ones are encouraged to submit applications.
Researchers in any field are encouraged to apply but the proposal must directly address blood cancer.
The Principal Investigator (Principal Applicant) must be based in, or formally affiliated with, a Canadian non-profit Sponsoring Institution at the time funding commences and for the duration of the award.
Applicants must hold a primary appointment that permits them to do independent research, supervise students, and publish their findings. Applications from non-academic facilities are not eligible. Applicants should hold a Ph.D., M.D., D.V.M. or equivalent degree. The Application will require one Principal Investigator (PI) who is responsible for the preparation and submission of the proposal including the budget, the conduct of the research programs and adherence with all stipulations made by LLSC, the LLSC Policies & Procedures document, and the Grant Agreement, if funded. The Principal Investigator must be able to demonstrate a significant track record in the area of hematology and/or blood cancer research.
Investigators must demonstrate that their research environment is equipped and suitable for the proposed study; this includes demonstrated access to patient materials, where applicable. Collaboration between multiple investigators to strengthen the proposed research will be considered favorably, but is not a requirement.
The PI must be an independent investigator, which is defined as a scientist who has dedicated laboratory space, directly hires and supervises laboratory personnel (technicians, graduate students, postdocs and staff scientists), and makes all decisions concerning research activities and use of the grant funds. The PI may not be a trainee or be in a subordinate position (i.e. directed or supervised by another), with respect to the subject matter of the proposed research/activities. Technical support personnel, postdoctoral fellows, research associates, Adjunct professors, status-only appointments, and investigators working outside of Canada are not permitted to apply as Principal Investigator.
For applicants who do not hold an eligible position, investigators can apply as Principal Investigators if they have a firm offer of an academic position (as described above) at an eligible Host Institution and the appointment is not dependent on the outcome of a pending application. However, the position must start by the grant’s start date. In these situations, a letter from an authorized representative of the Host Institution is required, outlining the precise nature of the appointment (including the position title and main tasks), as well as the anticipated start date and duration of the appointment.
“Co-principal investigator” or “co- principal applicant” refers to a researcher who will be in charge of specific administrative and scientific aspects of the research project, whether or not that researcher has a formal relationship with the Host Institution. Adjunct professors and appointments that are for status only can fall under these categories. These individuals are not eligible to receive grant-funded salary support. Graduate students, postdoctoral fellows, research associates, technical support employees, and investigators working outside of Canada are not included under these categories.
A “collaborator” or “co-investigator” refers to individuals who will make substantial intellectual contributions to the research project or have contributed to the drafting of the application itself, but who are not eligible to be included as “Co-Principal Investigators” or “Co-applicants”. Students, postdoctoral fellows, research associates, lay contributors (including patient partners) and investigators based outside of Canada may be included in this category. Students, postdoctoral fellows and research associates may receive salary support from a grant.
Individuals who have been affected by cancer are considered community/patient/survivor/caregiver participants/partners. This category may include anyone who is at high risk of cancer, has been diagnosed with cancer, or provides physical and emotional care to someone with cancer but not in a professional or vocational capacity. Community partners and caregivers can act as “collaborators” or “co-investigators” depending on responsibilities and impact of contribution to the proposed project.
For any questions of eligibility or unusual circumstances not described above, please contact LLSC.
A Principal Investigator may only submit ONE Application per application cycle and cannot serve as a Principal Investigator OR Co-Principal Investigator on more than ONE Application per cycle. A Co-Investigator (also known as Collaborator) CAN serve as Co-Investigator on more than one Application. A Principal Investigator or Co-Principal Investigator can serve as a Collaborator on other Applications (See Definitions below).
Eligible Countries:
Sponsor Institute/Organizations: LLSC Operating Grant
Address: 2 Lansing Square, Suite 601, Toronto, ON M2J 4P8, Canada
Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.
Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.
Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.
Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.
Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.
Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.
Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.
Nov 06, 2024
Feb 05, 2025
$100,000
up to 200,000
Affiliation: LLSC Operating Grant
Address: 2 Lansing Square, Suite 601, Toronto, ON M2J 4P8, Canada
Website URL: https://www.bloodcancers.ca/operating-grant
Disclaimer:It is mandatory that all applicants carry workplace liability insurance, e.g., https://www.protrip-world-liability.com (Erasmus students use this package and typically costs around 5 € per month - please check) in addition to health insurance when you join any of the onsite Trialect partnered fellowships.